STAT44%
GOP lawmakers push Trump’s FDA to make sure clinical trials are diverse 61%
By John Wilkerson0%
7/6/2026, 8:30:00 AM
BS Summary: This article contains 12 faulty reasoning types, including Negativity Bias, Post Hoc (False Cause), and Biased Writer Voice, with Framing Effect as the most egregious example at 50% saturation with 67 hits. Analysis detected 347 faulty-reasoning hits from 134 analyzed words, generating a BS Score of 56.5% and a BS Rank of 61% (8,651 of 21,887 articles). This article is worse (more manipulative) than 60.50% of the article peer group.
WASHINGTON — Clinical trial policy got caught up in the Trump administration’s attack on policies related to diversity, equity, and inclusion.
Republicans in Congress would like to change that.
Days after Trump took office, the Health and Human Services Department began purging all references to DEI from the websites of its agencies.
Those efforts were supposed to target DEI initiatives focused on hiring practices, communications, and social issues.
But supporters of clinical trial diversity say the policy has nothing to do with DEI in that sense.
Instead, it aims to ensure that clinical trials enroll people who are similar to the patients who would use the drugs and medical devices being tested.
To read the rest of this story subscribe to STAT+.
Speakers
Loading…
Loading…
Loading…
Loading…
Analysis
Hover over highlighted words in the article to view the associated bias or fallacy analysis.